Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Authors
Category Primary study
JournalBlood
Year 2019
This article has no abstract
Epistemonikos ID: a8a1ceaad2b60cf7a9fef01271b642e5a130338e
First added on: Feb 11, 2025